Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/15183
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Armstrong, Paul W. | - |
dc.contributor.author | Gershlick, Anthony H. | - |
dc.contributor.author | Goldstein, Patrick | - |
dc.contributor.author | Wilcox, Robert | - |
dc.contributor.author | Danays, Thierry | - |
dc.contributor.author | Lambert, Yves | - |
dc.contributor.author | Sulimov, Vitaly | - |
dc.contributor.author | Rosell Ortiz, Fernando | - |
dc.contributor.author | Ostojic, Miodrag | - |
dc.contributor.author | Welsh, Robert C. | - |
dc.contributor.author | Carvalho, Antonio C. | - |
dc.contributor.author | Nanas, John | - |
dc.contributor.author | Arntz, Hans-Richard | - |
dc.contributor.author | Halvorsen, Sigrun | - |
dc.contributor.author | Huber, Kurt | - |
dc.contributor.author | Grajek, Stefan | - |
dc.contributor.author | Fresco, Claudio | - |
dc.contributor.author | Bluhmki, Erich | - |
dc.contributor.author | Regelin, Anne | - |
dc.contributor.author | Vandenberghe, Katleen | - |
dc.contributor.author | BOGAERTS, Kris | - |
dc.contributor.author | Van de Werf, Frans | - |
dc.date.accessioned | 2013-06-05T08:11:09Z | - |
dc.date.available | 2013-06-05T08:11:09Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | NEW ENGLAND JOURNAL OF MEDICINE, 368 (15), p. 1379-1387 | - |
dc.identifier.issn | 0028-4793 | - |
dc.identifier.uri | http://hdl.handle.net/1942/15183 | - |
dc.description.abstract | BACKGROUND It is not known whether prehospital fibrinolysis, coupled with timely coronary angiography, provides a clinical outcome similar to that with primary percutaneous coronary intervention (PCI) early after acute ST-segment elevation myocardial infarction (STEMI). METHODS Among 1892 patients with STEMI who presented within 3 hours after symptom onset and who were unable to undergo primary PCI within 1 hour, patients were randomly assigned to undergo either primary PCI or fibrinolytic therapy with bolus tenecteplase (amended to half dose in patients >= 75 years of age), clopidogrel, and enoxaparin before transport to a PCI-capable hospital. Emergency coronary angiography was performed if fibrinolysis failed; otherwise, angiography was performed 6 to 24 hours after randomization. The primary end point was a composite of death, shock, congestive heart failure, or reinfarction up to 30 days. RESULTS The primary end point occurred in 116 of 939 patients (12.4%) in the fibrinolysis group and in 135 of 943 patients (14.3%) in the primary PCI group (relative risk in the fibrinolysis group, 0.86; 95% confidence interval, 0.68 to 1.09; P = 0.21). Emergency angiography was required in 36.3% of patients in the fibrinolysis group, whereas the remainder of patients underwent angiography at a median of 17 hours after randomization. More intracranial hemorrhages occurred in the fibrinolysis group than in the primary PCI group (1.0% vs. 0.2%, P = 0.04; after protocol amendment, 0.5% vs. 0.3%, P = 0.45). The rates of nonintracranial bleeding were similar in the two groups. CONCLUSIONS Prehospital fibrinolysis with timely coronary angiography resulted in effective reperfusion in patients with early STEMI who could not undergo primary PCI within 1 hour after the first medical contact. However, fibrinolysis was associated with a slightly increased risk of intracranial bleeding. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT00623623.) | - |
dc.description.sponsorship | Funded by Boehringer Ingelheim Supported by Boehringer Ingelheim. Dr. Armstrong reports receiving consulting fees from Eli Lilly, Merck, and Roche, payment for the development of educational presentations from AstraZeneca and Eli Lilly, and grant support through his institution from Merck; Dr. Goldstein, serving as a board member for Eli Lilly, Daiichi Sankyo, and the Medicines Company and receiving consulting fees from Eli Lilly, Daiichi Sankyo, the Medicines Company, and AstraZeneca, lecture fees from Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, AstraZeneca, the Medicines Company, Sanofi, and Bayer, and payment for the development of educational presentations from AstraZeneca and Boehringer Ingelheim; Dr. Wilcox, being a board member for and receiving consulting fees through his institution from Schering-Plough, Eli Lilly, Daiichi Sankyo, and AstraZeneca; Drs. Danays, Bluhmki, and Regelin, being employees of Boehringer Ingelheim; Dr. Lambert, receiving lecture fees from Boehringer Ingelheim; Dr. Sulimov, receiving lecture fees from Boehringer Ingelheim, Sanofi-Aventis, AstraZeneca, Bayer, Bristol-Myers Squibb, and Abbott; Dr. Rosell Ortiz, receiving lecture fees from Daiichi Sankyo and AstraZeneca; Dr. Welsh, receiving consulting fees from AstraZeneca, Eli Lilly, Roche, Medtronic, and Bayer, lecture fees from AstraZeneca and Eli Lilly, grant support from AstraZeneca and Edwards Lifesciences, and payment for the development of educational presentations from Bayer, AstraZeneca, and Eli Lilly; Dr. Nanas, receiving payment from Novartis, Sanofi-Aventis, and Actelion as principal investigator and to his institution for each patient enrolled in a multi-center trial; Dr. Halvorsen, receiving lecture fees from Bristol-Myers Squibb, AstraZeneca, Eli Lilly, Boehringer Ingelheim, and Bayer, travel reimbursement from Bristol-Myers Squibb, Eli Lilly, and Bayer, and payment for the development of educational presentations from AstraZeneca; Dr. Grajek, receiving consulting fees and payment for manuscript preparation from AstraZeneca and Servier, lecture fees from AstraZeneca, Servier, and Bayer, and payment for the development of educational presentations from AstraZeneca, Servier, Bayer, Merck, Sanofi-Aventis, and Berlin-Chemie; Dr. Fresco, receiving consulting fees from Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, and the Medicines Company and lecture fees from Boehringer Ingelheim, Eli Lilly, the Medicines Company, Pfizer, Bristol-Myers Squibb, and AstraZeneca; Dr. Bogaerts, receiving consulting fees through his institution from Boehringer Ingelheim; and Dr. Van de Werf, receiving consulting and lecture fees from Boehringer Ingelheim and grant support through his institution from Boehringer Ingelheim. No other potential conflict of interest relevant to this article was reported. | - |
dc.language.iso | en | - |
dc.publisher | MASSACHUSETTS MEDICAL SOC | - |
dc.rights | Copyright © 2013 Massachusetts Medical Society. | - |
dc.subject.other | Medicine, General & Internal | - |
dc.title | Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 1387 | - |
dc.identifier.issue | 15 | - |
dc.identifier.spage | 1379 | - |
dc.identifier.volume | 368 | - |
local.format.pages | 9 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Van De Werf, F (reprint author),Katholieke Univ Leuven, Univ Hosp Leuven, Dept Cardiovasc Sci, Herestr 49, B-3000 Louvain, Belgium. Univ Alberta, Canadian Virtual Coordinating Ctr Global Collabor, Edmonton, AB, Canada. Univ Alberta, Mazankowski Alberta Heart Inst, Edmonton, AB, Canada. Univ Hosp Leicester Trust, Leicester Cardiovasc Biomed Res Unit, Natl Inst Hlth Res, Leicester, Leics, England. Univ Nottingham, Dept Cardiovasc Med, Nottingham NG7 2RD, England. Lille Univ Hosp, Emergency Dept, Lille, France. Lille Univ Hosp, SAMU, Lille, France. Boehringer Ingelheim GmbH & Co KG, Reims, France. Ctr Hosp Versailles, SAMU 78, Versailles, France. Mobile Intens Care Unit, Versailles, France. First Moscow State Med Univ, Dept Internal Dis, Moscow, Russia. Empresa Publ Emergencias Sanitarias, Almeria, Spain. Univ Belgrade, Sch Med, Belgrade, Serbia. Univ Fed Sao Paulo, Dept Med, Div Cardiol, Sao Paulo, Brazil. Univ Athens, Dept Cardiol 3, GR-10679 Athens, Greece. Benjamin Franklin Med Ctr, Charite, Berlin, Germany. Univ Oslo, Ulleval Hosp, Dept Cardiol, Oslo, Norway. Wilhelminenhosp, Dept Med Cardiol & Emergency Med 3, Vienna, Austria. Poznan Univ Med Sci, Dept Cardiol, Poznan, Poland. Azienda Osped Univ Udine, Dept Cardiothorac Sci, Udine, Italy. Boehringer Ingelheim GmbH & Co KG, Biberach, Germany. Boehringer Ingelheim GmbH & Co KG, Basel, Switzerland. Katholieke Univ Leuven, Dept Cardiovasc Sci, B-3000 Louvain, Belgium. Katholieke Univ Leuven, Interuniv Inst Biostat & Stat Bioinformat, B-3000 Louvain, Belgium. Univ Hasselt, Hasselt, Belgium. frans.vandewerf@med.kuleuven.be | - |
local.publisher.place | WALTHAM | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1056/NEJMoa1301092 | - |
dc.identifier.isi | 000317333600005 | - |
item.validation | ecoom 2014 | - |
item.contributor | Armstrong, Paul W. | - |
item.contributor | Gershlick, Anthony H. | - |
item.contributor | Goldstein, Patrick | - |
item.contributor | Wilcox, Robert | - |
item.contributor | Danays, Thierry | - |
item.contributor | Lambert, Yves | - |
item.contributor | Sulimov, Vitaly | - |
item.contributor | Rosell Ortiz, Fernando | - |
item.contributor | Ostojic, Miodrag | - |
item.contributor | Welsh, Robert C. | - |
item.contributor | Carvalho, Antonio C. | - |
item.contributor | Nanas, John | - |
item.contributor | Arntz, Hans-Richard | - |
item.contributor | Halvorsen, Sigrun | - |
item.contributor | Huber, Kurt | - |
item.contributor | Grajek, Stefan | - |
item.contributor | Fresco, Claudio | - |
item.contributor | Bluhmki, Erich | - |
item.contributor | Regelin, Anne | - |
item.contributor | Vandenberghe, Katleen | - |
item.contributor | BOGAERTS, Kris | - |
item.contributor | Van de Werf, Frans | - |
item.fulltext | With Fulltext | - |
item.accessRights | Restricted Access | - |
item.fullcitation | Armstrong, Paul W.; Gershlick, Anthony H.; Goldstein, Patrick; Wilcox, Robert; Danays, Thierry; Lambert, Yves; Sulimov, Vitaly; Rosell Ortiz, Fernando; Ostojic, Miodrag; Welsh, Robert C.; Carvalho, Antonio C.; Nanas, John; Arntz, Hans-Richard; Halvorsen, Sigrun; Huber, Kurt; Grajek, Stefan; Fresco, Claudio; Bluhmki, Erich; Regelin, Anne; Vandenberghe, Katleen; BOGAERTS, Kris & Van de Werf, Frans (2013) Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction. In: NEW ENGLAND JOURNAL OF MEDICINE, 368 (15), p. 1379-1387. | - |
crisitem.journal.issn | 0028-4793 | - |
crisitem.journal.eissn | 1533-4406 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
nejmoa1301092 (1).pdf Restricted Access | Published version | 611.74 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.